The british HIV association/British association for sexual health and HIV position statement on pre-exposure prophylaxis in the UK

International Journal of STD and AIDS

Volumn 23, Issue 1, 2012, Pages 1-4

  McCormack, S ^a   Fidler, S ^b   Fisher, M ^c  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Worthing Hospital   (United Kingdom)

Author keywords

Guideline; HIV; HIV prevention; Pre exposure prophylaxis; PrEP; UK

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ARTICLE; BEHAVIOR CHANGE; CONDOM; CONSULTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SOCIETY; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; SEXUAL HEALTH; UNITED KINGDOM;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS;

EID: 84857476631     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.051211     Document Type: Article

References (21)

1. Health Protection Agency. HIV in the United Kingdom. London: Health Protection Agency, 2011. See http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317131685847 (last accessed 8 February 2012)
2. Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99
3. http://depts.washington.edu/uwicrc/research/studies/files/PrEP_PressRelease-UW_13Jul2011.pdf (last accessed 16 January 2012)
4. http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals.html (last accessed 16 January 2012)
5. Abdool Karim Q, Abdool Karim SS, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74
6. http://www.fhi360.org/en/Research/Projects/FEM-PrEP.htm (last accessed 8 February 2012)
7. VOICE: http://www.mtnstopshiv.org/node/3619 (last accessed 16 January 2012)
8. http://www.cdc.gov/nchhstp/newsroom/PrEPMSMGuidanceGraphic.html (last accessed 16 January 2012)
9. http://www.bashh.org/guidelines; http://www.bhiva.org/ClinicalGuidelines.aspx (last accessed 16 January 2012)
10. Weller S, David K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;1:CD003255
11. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505
12. Attia S, Egger M, Müller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009;23:1397-404
13. Weiss HA, Halperin D, Bailey RC, et al. Male circumcision for HIV prevention: from evidence to action? AIDS 2008;22:567-74
14. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485-90
15. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Eng J Med 2010;362:427-39
16. Hallett TB, Alsallaq RA, Baeten JM, et al. Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. Sex Transm Infect 2011;87:88-93
17. Drezett J. Post-exposure prophylaxis in raped women. IV International Conference on HIV Infection in Women and Children, Livro De Resumos, Universidade, Federal do Rio De Janeiro e Institute of Virology of Maryland, Rio de Janeiro, Brazil, 2002
18. Hendrix C, Minnis A, Guddera V, et al. A Phase II cross-over study of daily oral and vaginal tenofovir in healthy sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. Abs 35LB. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011
19. Sánchez J, Sal Y, Rosas VG, Hughes JP, et al. Male circumcision and risk of HIV acquisition among MSM. AIDS 2011;25:519-23
20. Schecter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004;35:519-25
21. Anton P, Cranston R, Carbello-Dieguez A, et al. RMP-02/MTN006 A phase I placebo controlled trial of rectally applied 1% vaginal tenofovir gel, with comparison to oral tenofovir. Abs 34LB. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011